Sugi Predict

Sugi Predict / Compounds / SCHEMBL7714728

SCHEMBL7714728

SCHEMBL7714728

O=C(O)ON1C(=O)CC(OCC2c3ccccc3-c3ccccc32)C1=O

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.39
▸ FABP5 Q01469 3/20 0.38
▸ FABP7 O15540 2/20 0.38
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ EPHX2 P34913 1/20 0.34
▸ CACNA1G O43497 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ EDNRB P24530 1/20 0.32
▸ EDNRA P25101 1/20 0.32
▸ MDM4 O15151 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ DPP8 Q6V1X1 1/20 0.32
▸ DPP9 Q86TI2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30876356 0.81 FABP5 (0.46) TSHRFABP5FABP7CA1CA2
SCHEMBL622854 0.81 FABP5 (0.46) TSHRFABP5FABP7CA1CA2
SCHEMBL30229708 0.80 TSHR (0.40) TSHRFABP5FABP7KMT2ACACNA1G
SCHEMBL334888 0.80 TSHR (0.40) TSHRFABP5FABP7KMT2ACACNA1G
SCHEMBL1279956 0.79 TSHR (0.40) TSHRFABP5FABP7KMT2ACACNA1G
SCHEMBL23748027 0.76 LMNA (0.36) TSHRKMT2ACACNA1GMAPTEDNRB
SCHEMBL5663756 0.73 FABP5 (0.43) TSHRFABP5FABP7CA1CA2
SCHEMBL472820 0.71 TSHR (0.41) TSHRFABP5FABP7CA1CA2
SCHEMBL19034829 0.68 TSHR (0.37) TSHRFABP5FABP7CA1CA2
Lithium Ion SCHEMBL1279955 0.68 TSHR (0.39) TSHRFABP5FABP7CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111153960-B A-type botulinum toxin inhibitor and preparation method and application thereof 中国人民解放军军事科学院军事医学研究院 2021-09-17 — — CN disclosed
US-20210206809-A1 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY VERA THERAPEUTICS INC (US) 2021-07-08 — — US disclosed
US-20210171437-A1 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO VERA THERAPEUTICS INC (US) 2021-06-10 — — US disclosed
EP-3655388-A1 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO Trucode Gene Repair, Inc. (US) 2020-05-27 — — EP disclosed
CN-111153960-A A-type botulinum toxin inhibitor and preparation method and application thereof 中国人民解放军军事科学院军事医学研究院 2020-05-15 — — CN disclosed
EP-3601237-A2 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY Trucode Gene Repair, Inc. (US) 2020-02-05 — — EP disclosed
CN-110740994-A Peptide Nucleic Acid (PNA) monomers with orthogonally protected ester moieties 特鲁科德基因修复公司 2020-01-31 — — CN disclosed
US-20190055190-A1 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO NEUBASE THERAPEUTICS, INC. 2019-02-21 — — US disclosed
WO-2019018422-A1 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO TRUCODE GENE REPAIR, INC. (US) 2019-01-24 — — WO disclosed
US-20180282375-A1 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY NEUBASE THERAPEUTICS, INC. 2018-10-04 — — US disclosed
WO-2018175927-A2 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY TRUCODE GENE REPAIR, INC. (US) 2018-09-27 — — WO disclosed
EP-0751150-B1 Cyclodextrin derivatives, their preparation and their use to incorporate hydrophobic molecules in organized surfactant systems COMMISSARIAT ENERGIE ATOMIQUE (FR) 2002-06-05 — — EP disclosed
US-5965524-A BIOSURFACTANTS, ANTIBACTERIAL, ANTIVIRAL AND ANTITRYPANOSOMAL THERAPEUTIC COMPOUNDS PEPTIDE TECHNOLOGIES CORPORATION (US) 1999-10-12 — — US disclosed
US-5821349-A Derivatives of cyclodextrins, their preparation and their use for incorporating hydrophobic molecules into organized surfactant systems COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1998-10-13 — — US disclosed
EP-0751150-A1 Cyclodextrin derivatives, their preparation and their use to incorporate hydrophobic molecules in organized surfactant systems COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1997-01-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190055190-A1 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO TARBP1, TIA1, SSB TSHR 158/4885FABP5 1276/4885FABP7 417/4885
US-20180282375-A1 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AGO2, TARBP1, TPR TSHR 105/4885FABP5 1227/4885FABP7 470/4885
US-20210171437-A1 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO TARBP1, TIA1, SSB TSHR 158/4885FABP5 1276/4885FABP7 417/4885
US-20210206809-A1 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AGO2, TARBP1, TPR TSHR 105/4885FABP5 1227/4885FABP7 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.